- Home
- YQ vs CLRB Comparison
YQ vs CLRB Comparison
Compare YQ & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- CLRB
- Stock Information
- Founded
- YQ 2012
- CLRB 2002
- Country
- YQ China
- CLRB United States
- Employees
- YQ N/A
- CLRB N/A
- Industry
- YQ Other Consumer Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- CLRB Health Care
- Exchange
- YQ Nasdaq
- CLRB Nasdaq
- Market Cap
- YQ 13.1M
- CLRB 10.7M
- IPO Year
- YQ 2020
- CLRB N/A
- Fundamental
- Price
- YQ $1.63
- CLRB $0.25
- Analyst Decision
- YQ
- CLRB Buy
- Analyst Count
- YQ 0
- CLRB 2
- Target Price
- YQ N/A
- CLRB $28.00
- AVG Volume (30 Days)
- YQ 42.7K
- CLRB 3.9M
- Earning Date
- YQ 12-11-2024
- CLRB 11-18-2024
- Dividend Yield
- YQ N/A
- CLRB N/A
- EPS Growth
- YQ N/A
- CLRB N/A
- EPS
- YQ N/A
- CLRB N/A
- Revenue
- YQ $28,507,378.00
- CLRB N/A
- Revenue This Year
- YQ N/A
- CLRB N/A
- Revenue Next Year
- YQ N/A
- CLRB N/A
- P/E Ratio
- YQ N/A
- CLRB N/A
- Revenue Growth
- YQ 22.55
- CLRB N/A
- 52 Week Low
- YQ $1.47
- CLRB $0.23
- 52 Week High
- YQ $3.55
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- YQ 31.56
- CLRB 5.84
- Support Level
- YQ $1.50
- CLRB $0.23
- Resistance Level
- YQ $1.92
- CLRB $0.28
- Average True Range (ATR)
- YQ 0.20
- CLRB 0.07
- MACD
- YQ -0.01
- CLRB -0.11
- Stochastic Oscillator
- YQ 16.13
- CLRB 1.41
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.